Research Index
SS-31 (Elamipretide) Research Index
PSI surfaces 50 peer-reviewed studies on SS-31 (Elamipretide), prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.
Nakagawa Y, Okazaki Y, Carballo CB et al.
JSES Int·2026·Human·PubMed →
Patient self-selection does not influence postoperative improvements in pain, function, or satisfaction in ream-and-run arthroplasty patients.
Suttmiller AMB, Snyder BA, Carofino BC
J Shoulder Elbow Surg·2026·Human·Osteoarthritis·PubMed →
RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy.
Karaa A, Goldstein A, Cohen BH et al.
Clin Genet·2026·Human·PubMed →
SS31 protects damaged retinal cells through the AMPK/DRP1 signaling pathway.
Cui N, Zhang RX, Yang Q et al.
Mol Vis·2026·Animal·PubMed →
Engineered Mitochondria-Targeted Biomimetic Hybrid Nanovesicles Ameliorate Rheumatoid Arthritis via Regulating Macrophage Autophagy and cGAS-STING Signaling.
Lu L, Su Y, Zheng L et al.
ACS Appl Mater Interfaces·2026·Animal·PubMed →
Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.
Xiao D, Cui X, Ali S et al.
Physiol Res·2026·Animal·Liver Fat (MASLD), Longevity·PubMed →
Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration.
Mei R, Zhang R, Li Z et al.
J Gastroenterol Hepatol·2026·Animal·PubMed →
Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target.
Li W, He R, Xie S et al.
Exp Neurol·2026·Animal·Neuroprotection·PubMed →
Chondrocyte membrane-camouflaged selenium nanoplatform with dual targeting for mitochondrial restoration and osteoarthritis therapy.
Zhang Z, Du Q, Zhu Z et al.
J Control Release·2026·Animal·Osteoarthritis·PubMed →
Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.
Muscat SM, Deems NP, Alvarez BD et al.
Brain Behav Immun·2026·Animal·PubMed →
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.
Xie L, Wu J, Fan J et al.
J Radiat Res·2026·Animal·Longevity·PubMed →
Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.
Fan J, Wu J, Yan S et al.
Biology (Basel)·2026·Animal·PubMed →
Elamipretide: a mitochondria-targeting drug for Barth syndrome.
Villatore A, Ehle EA, Chelko SP
Trends Pharmacol Sci·2026·Animal·PubMed →
Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.
Yang Q, Zhang Y, Liu P et al.
Neurochem Res·2026·Animal·Neuroprotection·PubMed →
Elamipretide in pediatric Barth syndrome: from heart failure to school return.
Amedro P, Andrianoely M, Gohier P et al.
Orphanet J Rare Dis·2026·Animal·PubMed →
AMCP Market Insights: Managed care considerations in Barth syndrome.
Flavin B, Vernon HJ, Todd Cade W et al.
J Manag Care Spec Pharm·2026·Animal·PubMed →
Topology-Controlled PEGylation Enhances Renal Accumulation of Therapeutic Peptide for Treating Ischemia-Reperfusion Injury.
Wen Y, Zhao Z, Zheng X et al.
Nano Lett·2026·Animal·PubMed →
Pre-qualifications, learning strategies, and study satisfaction among medical students: insights from a multicenter German study.
Schröpel C, Herrmann-Werner A, Festl-Wietek T et al.
Med Educ Online·2026·Animal·Cognitive Enhancement·PubMed →
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.
Vahle B, Weidner S, Tomalka A et al.
Circ Heart Fail·2026·Animal·Muscle Recovery·PubMed →
Is an emerging pharmacotherapeutic era for rare mitochondrial diseases here?
Bedoyan JK, Vockley J
Cell Metab·2026·Animal·PubMed →
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.
Stefaniak E, Cui B, Yan X et al.
Chem Biol Drug Des·2026·Animal·PubMed →
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.
Song Z, Ban Z, Zhao H et al.
Neurochem Int·2026·Animal·Neuroprotection·PubMed →
SLC25A28 Ameliorates Hyperoxic Lung Injury by Improving Mitochondrial Oxidative Phosphorylation in Alveolar Epithelial Cells.
Lu T, Chen SQ, Li SH et al.
Int J Mol Sci·2026·Animal·PubMed →
Protective Effect of Mitochondria-Targeted Polydopamine Nanoparticles in Alleviating Hepatic Ischemia-Reperfusion Injury.
Huang Y, Cui X, You J et al.
ACS Nano·2026·Animal·Liver Protection·PubMed →
Peroxiredoxin Ⅲ safeguards cardiac function against doxorubicin by regulating mitochondrial quality control via H(2)O(2) detoxification.
Park JW, Jang SY, Kim MY et al.
Redox Biol·2026·Animal·PubMed →
Mitochondria-Targeted Liposomes Boost Thermogenesis for Adipose Tissue Regulation.
Tian S, Xie H, Zhong Q et al.
Adv Healthc Mater·2026·Animal·Weight Loss·PubMed →
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
Elmorsy EA, Amer MM, Hamad RS et al.
Tissue Cell·2026·Animal·PubMed →
Dual action of SS31 via NRF2/HO-1: countering oxidative stress and metabolic dysfunction in ovarian aging.
Zhang G, Du X, Zhao Y et al.
J Ovarian Res·2026·Animal·Longevity·PubMed →
Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis.
Dong W, Zhang W, Huang L et al.
J Adv Res·2026·Animal·PubMed →
Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.
Xie M, Weng J, Li C et al.
Lung·2026·Animal·PubMed →
Association of hippocampus, entorhinal cortex, and amygdala with thyroid function: a bilateral volumetric analysis.
Hallab A, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Thyroid Res·2026·Animal·PubMed →
Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.
Ravichandran VS, Schatz TM, Lavey E et al.
Am J Physiol Heart Circ Physiol·2026·Animal·PubMed →
Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.
Muscat SM, Deems NP, Alvarez BD et al.
bioRxiv·2026·Animal·PubMed →
HA/CD44-SS31 Mitochondrial Targeting of Manganese Oxide Nanozymes for Ischemia-Reperfusion-Induced Acute Kidney Injury Therapy.
Lin Z, Zhou E, Zhang D et al.
ACS Nano·2026·Animal·PubMed →
The mitochondria-targeted peptide HDAP2 reduces mitochondrial loss and retinal ganglion cell degeneration after optic nerve injury.
MacNeil MA, Arain S, Mentor W et al.
Neuroscience·2026·Animal·Neuroprotection·PubMed →
SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism.
Xiong D, Zhang Y, Wei J et al.
J Ovarian Res·2026·Animal·Longevity·PubMed →
Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF.
Schauer A, Jahn D, Vahle B et al.
Int J Mol Sci·2026·Animal·PubMed →
Real-world disease burden and health care resource utilization for patients with Barth syndrome.
Marjoram L, Huang Y, Koenig MK et al.
J Med Econ·2025·Human·PubMed →
Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.
Jacob N, Schecter D, Marshall M et al.
Mol Genet Metab·2025·Human·PubMed →
Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.
Prasanpanich M, Husain M, Halnon NJ et al.
Cardiovasc Pathol·2025·Human·PubMed →
Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.
Gwaltney C, Shields A, Love E et al.
Orphanet J Rare Dis·2025·Human·PubMed →
Examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived iPSC cardiomyocytes.
Vaziri N, Shutt TE, Karim W et al.
Mol Psychiatry·2025·Human·Anti-Inflammatory·PubMed →
Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.
Ortmann L, Velasco D, Cole J
Eur Heart J Case Rep·2025·Human·PubMed →
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.
Ehlers JP, Hu A, Boyer D et al.
Ophthalmol Sci·2025·Human·PubMed →
Expanded-access use of elamipretide in a critically ill patient with Barth syndrome.
Goldstein AC, Pantano C, Redko M et al.
Genet Med Open·2024·Human·PubMed →
Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.
Ansari S, Koenig MK
Clin Case Rep·2024·Human·PubMed →
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.
Karaa A, Bertini E, Carelli V et al.
Orphanet J Rare Dis·2024·Human·PubMed →
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Sherrod CF 4th, Saberi S, Nassif ME et al.
J Am Coll Cardiol·2024·Human·PubMed →
Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
Patino J, Clearman AH, Miller L et al.
Clin Case Rep·2024·Human·PubMed →
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Thompson WR, Manuel R, Abbruscato A et al.
Genet Med·2024·Human·PubMed →